List of Excipients in Branded Drug URECHOLINE

« Back to Dashboard

Generic Drugs Containing URECHOLINE

Company	Ingredient	NDC	Excipient
Teva Women's Health Inc	bethanechol chloride	51285-691	ANHYDROUS LACTOSE
Teva Women's Health Inc	bethanechol chloride	51285-691	CELLULOSE, MICROCRYSTALLINE
Teva Women's Health Inc	bethanechol chloride	51285-691	D&C YELLOW NO. 10
Teva Women's Health Inc	bethanechol chloride	51285-691	FD&C YELLOW NO. 6
Teva Women's Health Inc	bethanechol chloride	51285-691	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in URECHOLINE?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	CELLULOSE, MICROCRYSTALLINE
1	D&C YELLOW NO. 10
1	FD&C YELLOW NO. 6
1	MAGNESIUM STEARATE

Urecholine Excipient Strategy and Commercial Opportunities for Bethanechol Chloride

Last updated: October 26, 2026

Urecholine is the historical brand name for bethanechol chloride, an oral direct-acting muscarinic agonist used primarily for postoperative or postpartum urinary retention and neurogenic bladder atony. Its commercial opportunity is not protected by meaningful brand exclusivity. The strongest opportunities are low-cost generic differentiation, liquid and orally disintegrating dosage forms, improved tolerability, and supply reliability.

Bethanechol chloride is a small-molecule, immediate-release drug with a mature regulatory history. The principal commercial barriers are limited market size, modest prescriber demand, cholinergic adverse effects, and the need to establish a clear clinical or adherence benefit for any reformulated product.

What is Urecholine and which active ingredient does it contain?

Urecholine contains bethanechol chloride. The drug is a synthetic choline ester with muscarinic activity and no meaningful nicotinic activity at therapeutic doses. It increases detrusor tone and gastrointestinal smooth-muscle activity.

Attribute	Urecholine and bethanechol chloride
Active ingredient	Bethanechol chloride
Historical brand	Urecholine
Dosage form	Immediate-release oral tablet
Historical strengths	5 mg, 10 mg, 25 mg, and 50 mg
Main uses	Urinary retention, neurogenic bladder atony, postoperative or postpartum bladder dysfunction
Pharmacologic class	Direct muscarinic cholinergic agonist
Regulatory pathway for copies	Abbreviated New Drug Application, generally under section 505(j)
Current commercial position	Mature generic market with limited brand differentiation
Key product risks	Abdominal cramping, diarrhea, sweating, flushing, bronchospasm, bradycardia, and hypotension

The FDA labeling instructs administration on an empty stomach, generally one hour before or two hours after meals, because food may increase nausea and other gastrointestinal effects.[1]

What excipients were used in Urecholine tablets?

Historical Urecholine tablet labeling identifies conventional immediate-release excipients, including lactose, starch, magnesium stearate, and colloidal silicon dioxide. Exact excipient composition can vary by strength, manufacturer, manufacturing period, and market presentation.[1]

These excipients indicate a conventional wet- or dry-granulated tablet platform rather than a modified-release or specialized delivery system.

Functional role of the historical excipients

Excipient	Likely formulation function	Commercial assessment
Lactose	Diluent and tablet-mass builder	Low cost and widely accepted, but unsuitable for some lactose-intolerant or dairy-avoidant patients
Starch	Binder, disintegrant, or filler	Established immediate-release excipient
Magnesium stearate	Lubricant	Effective at low concentrations; excessive use can slow dissolution
Colloidal silicon dioxide	Glidant and moisture-flow aid	Useful for powder flow and manufacturing consistency

A generic manufacturer does not need to duplicate the historical excipient system unless the product relies on an approved sameness strategy or the formulation is being developed to match a reference product. The formulation must comply with applicable inactive-ingredient requirements, quality standards, and bioequivalence expectations.

What excipient strategy is most suitable for bethanechol chloride?

The preferred strategy is a robust, low-cost immediate-release platform with rapid disintegration, low moisture sensitivity, and minimal gastrointestinal burden.

Conventional generic tablet

A standard tablet remains the lowest-risk product. Suitable excipient options include:

• Microcrystalline cellulose or lactose as diluent
• Crospovidone, croscarmellose sodium, or sodium starch glycolate as superdisintegrant
• Povidone or hydroxypropyl cellulose as binder
• Colloidal silicon dioxide as glidant
• Magnesium stearate or sodium stearyl fumarate as lubricant

A direct-compression formulation could reduce manufacturing steps. However, bethanechol chloride loading is low at the 5 mg and 10 mg strengths, making content uniformity and blend segregation important development controls.

Lactose-free tablet

A lactose-free formulation could differentiate a generic product without requiring a novel delivery system. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, or selected starches could replace lactose.

The commercial value is limited because lactose intolerance is not a major labeled contraindication for bethanechol. The product would need a clear pharmacy or institutional purchasing advantage, such as broader formulary acceptability or simpler excipient declarations.

Orally disintegrating tablet

An orally disintegrating tablet could target patients who have difficulty swallowing, including older adults with neurogenic bladder, postoperative patients, and patients receiving multiple medicines.

A practical ODT system could use:

• Mannitol for mouthfeel and rapid dissolution
• Crospovidone or low-substituted hydroxypropyl cellulose for disintegration
• Aspartame, sucralose, or a sugar alcohol for taste correction
• A low-level flavor system
• Sodium stearyl fumarate or magnesium stearate for lubrication

Taste masking is a central technical issue. Bethanechol has a cholinergic, potentially bitter or otherwise unpleasant taste. Ion-exchange resin complexes, polymer coating, cyclodextrin systems, or multiparticulate coating could improve palatability, but each adds cost and regulatory complexity.

Oral solution or suspension

A liquid product offers the clearest unmet formulation opportunity. It could serve patients who cannot swallow tablets and permit dose titration below the available tablet strengths.

Key development issues include:

• Chemical and microbial stability
• Preservative selection
• pH control
• Container compatibility
• Dose-measuring accuracy
• Taste masking
• Excipient suitability for pediatric or geriatric use

A sugar-free solution using sorbitol, glycerin, or a combination of sweeteners could reduce sugar exposure. A unit-dose cup, oral syringe, or ready-to-administer sachet could support institutional use.

The product should avoid unnecessary excipients associated with age-related or disease-related concerns, including high ethanol levels, excessive propylene glycol, and poorly tolerated preservatives.

What formulations are commercially attractive for Urecholine?

The strongest opportunities are ranked below.

Formulation	Development burden	Differentiation	Commercial potential
Standard generic tablet	Low	Low	Moderate in a shortage or supply-constrained market
Lactose-free tablet	Low to moderate	Low	Limited to moderate
ODT	Moderate	Moderate	Moderate
Sugar-free oral solution	Moderate to high	High	Moderate to high in institutional and dysphagia segments
Powder for reconstitution	Moderate	Moderate	Moderate, with stability and reconstitution controls
Extended-release product	High	High	Uncertain because the approved clinical use is generally immediate-release and dose titration may be important
Transdermal or parenteral product	High	High	Low without substantial clinical redevelopment

An oral solution is more commercially defensible than an extended-release product. Modified release could reduce dosing frequency, but bethanechol’s clinical use and cholinergic tolerability may not support prolonged exposure. A new pharmacokinetic profile would likely require more extensive clinical justification.

When does Urecholine lose exclusivity?

Urecholine’s original small-molecule exclusivity and patent protection are historical matters. Bethanechol chloride is a mature generic active ingredient, and the original product is not positioned as a current, patent-protected innovation.

The FDA’s Orange Book is the primary source for current listed patents and regulatory exclusivity. Patent claims must be assessed by product, dosage form, holder, and listed use. A new manufacturer should not assume that the absence of a marketed brand eliminates all regulatory or formulation risk, but a conventional bethanechol tablet generally presents a low patent barrier compared with recently approved drugs.[2]

Exclusivity timeline

Milestone	Commercial implication
Original Urecholine approval	Established the reference-product history
Expiration of historical small-molecule rights	Enabled generic competition
Current generic availability	Limits pricing power for conventional tablets
New ODT or liquid approval	Could create product-specific differentiation
New patentable formulation	May support limited formulation exclusivity if claims are novel and non-obvious
New clinical use	Could support method-of-use rights, subject to statutory and listing requirements

No commercial strategy should depend on old Urecholine brand rights. The defensible asset would be a new formulation, device, packaging system, manufacturing process, or clinically supported use.

What is the Orange Book status of Urecholine?

The Orange Book determines whether an approved reference product has listed patents, exclusivity, therapeutic-equivalence evaluations, and approved dosage forms.[2] Bethanechol products may appear under the active ingredient rather than under the historical Urecholine brand.

For a conventional generic, the principal regulatory route is an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the applicable reference-listed drug. If the target product is an oral solution, ODT, or other dosage form without a suitable reference product, a 505(b)(2) application may be more appropriate.

The regulatory route affects both time and patent strategy:

Product concept	Likely pathway
Same-strength immediate-release tablet	505(j) ANDA
Different inactive ingredients but same dosage form	Usually 505(j), subject to sameness and bioequivalence requirements
ODT without an equivalent reference product	Potentially 505(b)(2)
New oral solution with new dosing or clinical claims	Potentially 505(b)(2)
New method of use	505(b)(2) or supplemental application, depending on product and data

Are there Paragraph IV challenges involving Urecholine?

Paragraph IV litigation is most relevant when an ANDA applicant challenges a listed patent in the Orange Book. Bethanechol chloride is an old generic drug, so large-scale, current Paragraph IV activity is unlikely to be the principal market issue.

For a new formulation, the risk shifts from legacy active-ingredient patents to formulation, dosage-form, manufacturing, and method-of-use patents. A sponsor should expect potential certification issues if a 505(b)(2) application relies on an approved product with listed patents.

A conventional tablet manufacturer is more likely to face commercial competition than patent litigation. The relevant risks are price erosion, shortage-driven entry, wholesaler access, and manufacturing economics.

What formulation patents could protect a new bethanechol product?

Potentially protectable subject matter includes:

• A stable aqueous bethanechol solution
• A taste-masked ODT
• A low-dose tablet with improved content uniformity
• A specific excipient ratio that improves dissolution or stability
• A unit-dose liquid presentation
• A controlled-release matrix with defined pharmacokinetic properties
• A manufacturing process that reduces degradation or blend segregation
• A formulation that avoids a problematic preservative or allergen

Patent strength would depend on unexpected technical results. Broad claims covering bethanechol plus routine excipients would face substantial obviousness risk. Stronger claims would require comparative data showing improved stability, dissolution, palatability, content uniformity, or clinical performance.

Which companies are challenging Urecholine’s market?

The relevant competitive group is not a single branded challenger. It includes:

1. Generic manufacturers of bethanechol chloride tablets.
2. Contract manufacturers with low-volume oral-solid-dose capacity.
3. Specialty companies developing liquid or geriatric dosage forms.
4. Compounding pharmacies supplying customized oral liquids.
5. Hospital suppliers seeking reliable procurement during generic shortages.

The market is likely fragmented and price-sensitive. A new entrant would need either a lower cost of goods, more reliable supply, a differentiated dosage form, or a channel-specific product.

How does Urecholine compare with competing urinary-retention products?

Bethanechol competes with non-drug management and other pharmacologic approaches rather than with a single direct branded substitute.

Approach	Main advantage	Main limitation
Bethanechol	Oral pharmacologic option for bladder atony	Cholinergic adverse effects and limited efficacy in some patients
Intermittent catheterization	Direct bladder emptying	Training, adherence, infection, and handling burden
Alpha-blocker therapy	Useful in selected obstructive conditions	Not a direct substitute for detrusor underactivity
Neostigmine or other cholinergic approaches	Pharmacologic activity	Greater administration and safety complexity
Surgical or procedural management	Addresses structural causes	Invasive and diagnosis-dependent

Bethanechol should not be positioned as a universal treatment for urinary retention. Its commercial opportunity is concentrated in appropriately diagnosed bladder atony and selected neurogenic or postoperative settings.

What licensing deals and partnerships could support a bethanechol product?

A licensing transaction would be most credible around a differentiated dosage form, not the active ingredient itself.

Potential deal structures include:

• Out-licensing an ODT technology to a generic manufacturer
• Contract manufacturing of a stable oral solution
• Hospital-system supply agreements
• Private-label distribution through specialty pharmacies
• Regional licensing for a pediatric or geriatric presentation
• Co-development with a company specializing in taste masking or oral thin films

The highest-value asset would combine formulation IP, regulatory documentation, validated manufacturing, and committed distribution. A standalone patent without manufacturing and market access would have limited value because the underlying drug is inexpensive and clinically mature.

What generic launch scenarios exist for Urecholine?

Low-cost tablet launch

This scenario offers the shortest development path but faces direct price competition. It is viable where the manufacturer has efficient tablet production or access to a shortage-affected market.

Differentiated ODT launch

This product could support a higher price if it demonstrates meaningful administration benefits. The main risks are taste, dose uniformity, packaging moisture protection, and the need to establish bioequivalence.

Oral solution launch

A liquid product could capture institutional, geriatric, and dysphagia demand. Commercial success would depend on stability, preservative acceptability, dosing-device accuracy, and pharmacy distribution.

Supply-security launch

A manufacturer could compete through reliable availability rather than formulation innovation. This strategy requires dual-source raw materials, validated backup manufacturing, and strong inventory management.

How strong is the patent estate for Urecholine?

The legacy patent estate is weak from a new-entry perspective because bethanechol chloride is an old active ingredient and conventional immediate-release tablets are established generic products. The stronger IP opportunity is prospective and formulation-specific.

IP category	Relative strength for a new entrant
Bethanechol active ingredient	Very low
Conventional tablet composition	Low
ODT taste masking	Moderate if supported by data
Stable oral solution	Moderate
Novel release profile	Potentially moderate to strong, but clinically demanding
Manufacturing process	Moderate if process-specific and difficult to design around
Packaging and dosing device	Moderate, usually narrow
New method of use	Dependent on clinical evidence and claim scope

Key Takeaways

• Urecholine is the historical brand for bethanechol chloride.
• The conventional tablet market is mature, generic, and price sensitive.
• The best excipient strategy is a robust immediate-release platform with rapid disintegration and low manufacturing cost.
• Lactose-free tablets offer modest differentiation; ODTs and oral solutions offer stronger commercial positioning.
• Taste masking, liquid stability, preservative selection, and dose accuracy are the central formulation issues.
• A conventional tablet is generally an ANDA opportunity, while a novel liquid or ODT may require a 505(b)(2) strategy.
• Legacy patent protection is unlikely to create a significant barrier; new formulation patents would carry the main strategic value.
• Commercial success is more likely to come from differentiated administration, supply reliability, or institutional contracting than from premium pricing for the active ingredient.

FAQs

Is bethanechol chloride still commercially available?

Bethanechol chloride remains a generic drug product, although availability can vary by manufacturer, strength, and distribution channel. Urecholine is primarily a historical brand reference.

Can a company market a liquid version of Urecholine?

Yes, but the regulatory pathway depends on the reference product, dosage form, formulation claims, and reliance on existing FDA findings. A novel oral solution may be developed through a 505(b)(2) application.

Which excipient is best for a bethanechol ODT?

Mannitol combined with a high-efficiency disintegrant such as crospovidone is a practical starting platform. The final choice depends on taste, tablet strength, mechanical properties, dissolution, and stability.

Does bethanechol have pediatric formulation potential?

A liquid or dispersible dosage form could improve dose flexibility for selected pediatric patients, but pediatric labeling, dosing evidence, palatability, and excipient safety would determine the commercial value.

What is the most defensible patent strategy for a new bethanechol product?

The strongest strategy would generally focus on a technically supported formulation or manufacturing improvement, such as stable liquid delivery, taste masking, improved content uniformity, or a validated dosage form with a clinically relevant administration advantage.

References

1. U.S. Food and Drug Administration. (n.d.). Urecholine (bethanechol chloride) tablets prescribing information. FDA/DailyMed labeling archive.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2019). Size, shape, and other physical attributes of generic tablets and capsules: Guidance for industry. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2022). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin. U.S. Department of Health and Human Services.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

6. U.S. Food and Drug Administration. (2023). Inactive ingredient database. Center for Drug Evaluation and Research.